Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research
Date (from‐to) : 2011 -2012
Author : IIJIMA Sayuki; TANAKA Yasuhito; WATANABE Tsunamasa; MATSUURA Kentarou; IIO Etsuko; HOJO Mayumi
Polymorphisms of IL28B (IFNλ3) have been reported as genetic factors that it associated with the response to pegylated IFN-alpha (PEG-IFNα) + ribavirin (RBV) treatment in chronic hepatitis C patients. However, details of IL28B functions are unknown. In this study, we examined the relevance of IL28B SNP and ISG induction by drug administration. Our subjects were the patients of Peg-IFNα + RBV therapy (dual therapy) or Peg-IFNα + RBV + protease inhibitor therapy (three-drug therapy). In the gene-expression of inhibitor factors, the result of HE/MI patients tended to be higher than the gene expression of MA patients immediately after a medical treatment start. We will also verify the relevance of the therapeutic effect to the ISG expression.